Burns - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Burns - Pipeline Review, H1 2019’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burns

- The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Burns therapeutics and enlists all their major and minor projects

- The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Burns

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Burns

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

Anterogen Co Ltd

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics ...

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

Anterogen Co Ltd

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

Phagelux Inc

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

viDA Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burns - Overview

Burns - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burns - Overview

Burns - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burns - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burns - Companies Involved in Therapeutics Development

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

Anterogen Co Ltd

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

Phagelux Inc

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

viDA Therapeutics Inc

Burns - Drug Profiles

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(chlorpheniramine maleate + ibuprofen) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGLE-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BH-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromelains - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epidermal growth factor biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJ-01SS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligomer G for Burn Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAAP-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Burns and Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tolasure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XF-70 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Jan 23, 2019: MediWound reports positive top-line data from NexoBrid study

Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in additional BARDA funding for pediatric studies of stratagraft skin tissue in thermal burns

Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to $43 Million for development of NexoBrid for sulfur mustard injuries

Sep 05, 2018: NexoBrid receives marketing authorization from Russia's Ministry of Health

Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy

Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study

Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health

Apr 09, 2018: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago

Jan 23, 2018: Amarantus Subsidiary Cutanogen Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Jan 04, 2018: Amarantus Subsidiary Cutanogen Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Oct 31, 2017: NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect

Sep 11, 2017: MediWound's NexoBrid Wins Best Poster Presentation Award at the 17th European Burns Association Congress

Sep 06, 2017: MediWounds NexoBrid Highlighted in 43 Presentations at the 17th European Burns Association Congress

Jul 19, 2017: BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid Indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Burns - Pipeline by AlgiPharma AS, H1 2019

Burns - Pipeline by Alliance Pharma Plc, H1 2019

Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1 2019

Burns - Pipeline by Anterogen Co Ltd, H1 2019

Burns - Pipeline by CFM Pharma Holding BV, H1 2019

Burns - Pipeline by Destiny Pharma Plc, H1 2019

Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2019

Burns - Pipeline by Madam Therapeutics BV, H1 2019

Burns - Pipeline by MallInckrodt Plc, H1 2019

Burns - Pipeline by MediWound Ltd, H1 2019

Burns - Pipeline by Phagelux Inc, H1 2019

Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2019

Burns - Pipeline by USV Pvt Ltd, H1 2019

Burns - Pipeline by viDA Therapeutics Inc, H1 2019

Burns - Dormant Projects, H1 2019

Burns - Dormant Projects, H1 2019 (Contd..1), H1 2019

Burns - Dormant Projects, H1 2019 (Contd..2), H1 2019

Burns - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports